Edwards Lifesciences

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

CEO

Bernard J. Zovighian

CEOBernard J. Zovighian

Employees

16,000

Employees16,000

Headquarters

Irvine, California

HeadquartersIrvine, California

Founded

1958

Founded1958

Employees

16,000

Employees16,000

EW Key Statistics

Market cap

60.21B

Market cap60.21B

Price-Earnings ratio

59.48

Price-Earnings ratio59.48

Dividend yield

—

Dividend yield—

Average volume

6.37M

Average volume6.37M

High today

$105.37

High today$105.37

Low today

$102.17

Low today$102.17

Open price

$102.81

Open price$102.81

Volume

6.12M

Volume6.12M

52 Week high

$105.37

52 Week high$105.37

52 Week low

$74.66

52 Week low$74.66

Stock Snapshot

The current Edwards Lifesciences(EW) stock price is $104.71, with a market capitalization of 60.21B. The stock trades at a price-to-earnings (P/E) ratio of 59.48.

During the trading session on 2026-11-10, Edwards Lifesciences(EW) shares reached a daily high of $105.37 and a low of $102.17. At a current price of $104.71, the stock is +2.5% higher than the low and still -0.6% under the high.

Trading activity shows a volume of 6.12M, compared to an average daily volume of 6.37M.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $105.37 and a low of $74.66.

EW News

Investing.com 21h

Edwards Lifesciences CVP Daveen Chopra sells $2.9M in stock - Investing.com

...

Simply Wall St 1d

What Edwards Lifesciences Stock Beat And Raised Outlook Means For Shareholders

Edwards Lifesciences reported third quarter 2026 sales of US$1,715.5 million and net income of US$307.5 million, and raised full year guidance for total sales g...

Simply Wall St 3d

Edwards Lifesciences Could Be 21% Undervalued After Earnings Guidance And Trial Data

Edwards Lifesciences (EW) is back in focus after a busy early November, with third quarter results, higher full year sales guidance and fresh clinical trial dat...

Analyst ratings

80%

of 30 ratings

Buy

80%

Hold

16.7%

Sell

3.3%

More EW News

Simply Wall St 4d

Edwards Lifesciences Stock Looks Fully Priced On Cash Flow

has delivered a strong share gain in recent years, and a fresh swing in sentiment after new clinical data now puts the spotlight squarely on one question for in...

Simply Wall St 5d

Edwards Lifesciences Trial Results Put Earlier TAVR Use In Focus

Edwards Lifesciences (NYSE:EW) reported that its PROGRESS Trial found clinical benefits for TAVR in moderate aortic stenosis patients. The study showed reducti...

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.